TENX Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. (TENX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: September 16, 2026 , by Doogan Declan .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Doogan Declan | Director | Buy | 53,000 | $1.92 | $101.8K | 55,274 | |
| Giordano Christopher Thomas | CEO | Buy | 4,850 | $1.82 | $8.8K | 22,174 | |
| Giordano Christopher Thomas | CEO | Buy | 6,000 | $1.88 | $11.3K | 17,324 | |
| STAAB THOMAS R II | Chief Financial Officer | Buy | 5,675 | $1.94 | $11.0K | 15,675 | |
| Buy | 900,000 | $1.78 | $1.6M | 6,524,151 | |||
| Buy | 187,704 | $1.80 | $337.6K | 5,624,151 | |||
| Buy | 179,058 | $1.80 | $321.6K | 5,436,447 | |||
| Buy | 403,571 | $1.79 | $722.6K | 5,257,389 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.